David Taussig
Overview
Explore the profile of David Taussig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, et al.
Blood Adv
. 2024 Sep;
8(21):5590-5597.
PMID: 39265176
Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after...
2.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda A, ONions J, et al.
Br J Haematol
. 2024 Jul;
205(4):1326-1336.
PMID: 38977430
Favourable outcomes with CPX-351 versus conventional 7 + 3 were demonstrated in the pivotal phase III trial in adults aged 60-75 years with newly diagnosed, highrisk/secondary acute myeloid leukaemia (AML)....
3.
Gunasekaran D, Rostovsky I, Taussig D, Bar-Am T, Wine Y, Sal-Man N, et al.
Biosens Bioelectron
. 2024 Apr;
257:116314.
PMID: 38663325
Diarrheagenic E. coli infections, commonly treated with β-lactam antibiotics, contribute to antibiotic resistance - a pressing public health concern. Rapid monitoring of pathogen antibiotic resistance is vital to combat antimicrobial...
4.
Pietka G, De Lord C, Matthias G, Cheung B, Atwal S, Furtado M, et al.
Br J Haematol
. 2024 Mar;
204(4):1325-1334.
PMID: 38462984
We report on a study of next-generation sequencing in 257 patients undergoing investigations for cytopenias. We sequenced bone marrow aspirates using a target enrichment panel comprising 82 genes and used...
5.
Dexter T, Taiwo T, Dearden C, Chan L, Taussig D, El-Sharkawi D, et al.
Br J Haematol
. 2024 Feb;
204(4):1554-1556.
PMID: 38407416
No abstract available.
6.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong I, et al.
Blood Adv
. 2023 Dec;
8(2):343-352.
PMID: 38039513
Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can...
7.
Kigel A, Vanetik S, Mangel L, Friedman G, Nozik C, Terracina C, et al.
Am J Clin Nutr
. 2023 Sep;
118(5):1068.
PMID: 37717944
No abstract available.
8.
Amir A, Taussig D, Bitton A, Nahary L, Vaisman-Mentesh A, Benhar I, et al.
Methods Mol Biol
. 2023 Sep;
2702:347-372.
PMID: 37679629
Antibody libraries came into existence 30 years ago when the accumulating sequence data of immunoglobulin genes and the advent of PCR technology made it possible to clone antibody gene repertoires....
9.
Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, et al.
Leukemia
. 2023 Aug;
37(10):2066-2072.
PMID: 37558736
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can...
10.
Kigel A, Vanetik S, Mangel L, Friedman G, Nozik C, Terracina C, et al.
Am J Clin Nutr
. 2023 Jul;
118(3):572-578.
PMID: 37479184
Background: The human milk antibody response following maternal immunization with the BNT162b2 mRNA vaccine is important for the protection of the infant during infancy. The vaccine-specific antibody response is still...